These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32368570)

  • 1. The Indian perspective of COVID-19 outbreak.
    Kaushik S; Kaushik S; Sharma Y; Kumar R; Yadav JP
    Virusdisease; 2020 Jun; 31(2):146-153. PubMed ID: 32368570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
    Bchetnia M; Girard C; Duchaine C; Laprise C
    J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye.
    Al-Sharif E; Strianese D; AlMadhi NH; D'Aponte A; dell'Omo R; Di Benedetto R; Costagliola C
    Int Ophthalmol; 2021 Jan; 41(1):349-362. PubMed ID: 32880786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview on the seven pathogenic human coronaviruses.
    Kesheh MM; Hosseini P; Soltani S; Zandi M
    Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.
    Zimmermann P; Curtis N
    Pediatr Infect Dis J; 2020 May; 39(5):355-368. PubMed ID: 32310621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronaviruses and SARS-COV-2.
    Hasöksüz M; Kiliç S; Saraç F
    Turk J Med Sci; 2020 Apr; 50(SI-1):549-556. PubMed ID: 32293832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection.
    Qin S; Xia X; Shi X; Ji X; Ma F; Chen L
    Bioinformatics; 2021 Jan; 36(21):5133-5138. PubMed ID: 32805023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Spectrum of COVID-19 Cases and their Correlation with S.LDH Levels- An Observational Study from Southeast Rajasthan.
    Gupta D; Sharma R; Patwardhan B; Mathur RD
    J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
    Tornesello AL; Botti C; Micillo A; Labonia F; Arpino S; Isgrò MA; Meola S; Russo L; Cavalcanti E; Sale S; Nicastro C; Atripaldi L; Starita N; Cerasuolo A; Reimer U; Holenya P; Buonaguro L; Buonaguro FM; Tornesello ML
    J Transl Med; 2023 Feb; 21(1):123. PubMed ID: 36788606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics.
    Siragam V; Maltseva M; Castonguay N; Galipeau Y; Srinivasan MM; Soto JH; Dankar S; Langlois M-A
    Microbiol Spectr; 2024 Jul; 12(7):e0422023. PubMed ID: 38864599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Patents and Advances on Nanotechnologies against Coronavirus.
    Abedini-Nassab R; Mahdaviyan N
    Recent Pat Nanotechnol; 2021; 15(4):322-330. PubMed ID: 33172382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
    Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ;
    mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Infection: Epidemiology, Virology, Clinical Features, Diagnosis and Pharmacological Treatment.
    Kaur A; Bhalla V; Salahuddin M; Rahman SO; Pottoo FH
    Curr Pharm Des; 2021; 27(33):3551-3565. PubMed ID: 33430745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
    Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
    Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
    Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
    Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.